Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

Abstract Background Twelve months treatment is the current standard of care for adjuvant trastuzumab in patients with HER2 positive early breast cancer however the optimal duration is not known. Persephone is a non-inferiority randomised controlled trial comparing 6- to 12-months of trastuzumab. In...

Full description

Bibliographic Details
Main Authors: Louise Hiller, Janet A. Dunn, Shrushma Loi, Anne-Laure Vallier, Donna L. Howe, David A. Cameron, David Miles, Andrew M. Wardley, Helena M. Earl
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Cancer
Subjects:
Breast Cancer
HER2 positive
Adjuvant trastuzumab duration
Trastuzumab cardiotoxicity
Investigator questionnaire
Online Access:http://link.springer.com/article/10.1186/s12885-018-4307-8

Internet

http://link.springer.com/article/10.1186/s12885-018-4307-8

Similar Items